Filing Details
- Accession Number:
- 0001611395-15-000002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-05-18 09:29:34
- Reporting Period:
- 2015-05-14
- Filing Date:
- 2015-05-18
- Accepted Time:
- 2015-05-18 09:29:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1349929 | Cancer Genetics Inc | CGIX | Services-Medical Laboratories (8071) | 043462475 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1611395 | E. Geoffrey Harris | 201 Rt 17 North, 2Nd Floor C/O Cancer Genetics, Inc. Rutherford NJ 07070 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-05-14 | 5,000 | $10.79 | 5,000 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2015-05-14 | 5,000 | $0.00 | 10,000 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2015-05-14 | 10,000 | $0.00 | 10,000 | $10.74 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 10,000 | 2016-05-14 | 2025-05-14 | No | 4 | A | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.74 to $10.80, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- The restricted stock underlying the award vests in two equal installments on May 14, 2016 and May 14, 2017, respectively.
- The option vests in two equal installments on May 14, 2016 and May 14, 2017, respectively.
Billionaire Hedge Funds
